Exposure to external environmental stimuli can lead to skin instability and dysfunction, resulting in hard-to-heal wounds, premature ageing, pigmentary disorders, hair loss, certain immune-mediated skin diseases and connective tissue disorders. Many current skin treatment methods have not yet achieved an ideal balance between medical rehabilitation and cosmetic needs. Exosomes are nanoscale vesicles derived from cells that carry various biomolecules, including proteins, nucleic acids and lipids, and can communicate with neighbouring or distant cells. Recent studies have shown that various endogenous exosomes are key regulators in shaping the physiological and pathological development of the skin. Furthermore, exogenous exosomes (such as those derived from stem cells) can serve as novel therapeutic options for repairing, regenerating, and revitalizing skin tissue. Exosomes possess unique physicochemical properties, such as the ability to cross tissue barriers and the mononuclear phagocyte system, as well as specific targeting capabilities when carrying drugs. Therefore, they are frequently used as therapeutic drug delivery vehicles in medical aesthetics. The lipid bilayer structure of exosomes, for example, can prolong the circulation time of drugs in the body, thereby circumventing clearance by the mononuclear phagocyte system and increasing local drug concentrations. This effectively regulates drug release. Compared with traditional nanomaterials, exosomes exhibit good biocompatibility, degradability, low toxicity and low immunogenicity, making them a more suitable drug delivery carrier. In response to demand for high-quality exosome technology, CD Bioparticles has launched a comprehensive range of cosmetic exosome products, including various plant extracts and fermentation products, to help customers accelerate their cosmetic R&D and product innovation. This product line provides scientists and product developers dedicated to exploring next-generation cosmetic formulations with reliable raw material support. These exosomes can support a variety of cosmetic application areas, including skin barrier repair, skin rejuvenation and anti-ageing research, the development of cosmetic formulations for skin hydration and elasticity, and customized cosmetic R&D services. In addition to its extensive exosome product range, CD Bioparticles provides technical support and custom services to help customers select the most suitable solutions for their specific R&D objectives. CD Bioparticles offers complete portfolio of exosome products and solutions to meet the growing demand for scientifically proven, high-efficacy topical ingredients. For detailed technical documentation, product specifications, or bulk inquiries regarding CD Bioparticles’ Exosomes for Cosmetics, please visit https://www.cd-bioparticles.net/products/exosomes-for-cosmetics.html. About CD Bioparticles CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.

Unlike electrochemiluminescence, direct chemiluminescence or enzyme-catalyzed chemiluminescence, homogeneous luminescence technology uses two types of markers: a luminescent material and a photosensitizer. The photosensitizer is distributed on the surface of donor polystyrene microspheres, while the chemiluminescent dye is distributed on the surface of acceptor polystyrene microspheres. These two types of microsphere interact via antigen-antibody binding, enabling the transfer of high-energy reactive oxygen species and triggering the light-induced chemiluminescence process. This makes “non-separation” homogeneous immunoassays possible, characterized by high precision and rapid detection. Based on this assay platform, CD Bioparticles has developed dozens of clinically relevant tests, including those for infectious disease biomarkers, serum tumour markers, thyroid function-related hormones, reproductive hormones and cardiac emergency markers. CD Bioparticles provides comprehensive solutions ranging from homogeneous assay raw materials to technical development and large-scale production. Leveraging extensive experience in innovative R&D and mass production, CD Bioparticles assists clients in developing homogeneous, chemiluminescence-based products, thereby reducing development costs and shortening R&D cycles. CD Bioparticles’ services cover every stage, from custom conjugation to optimizing complete assay systems. This includes evaluating and screening antibodies and antigens, selecting donors and acceptors for custom antigen/antibody conjugation, optimizing conjugation conditions, optimizing reaction systems (including sample volume, donor and acceptor concentrations, and buffer systems), and validating assays. These homogeneous chemiluminescent assays can be used for biomarker detection for in vitro diagnostics (IVD), detecting protein-protein interactions, and identifying post-translational modifications. CD Bioparticles’ homogeneous chemiluminescent immunoassay development services are tailored to the unique needs of each research project. Its team of experts provides end-to-end support, including assay design, optimization, and post-market assistance. The company offers scalable, cost-effective solutions, with production processes capable of meeting a wide range of throughput requirements—from small-scale R&D needs to large-scale commercial production. Additionally, CD Bioparticles provides high-quality donors and receptors with diverse surface characteristics and consistent quality to accommodate various conjugation methods. The company possesses extensive experience in assay design, raw material selection, conjugation and buffer system optimization, and assay validation. CD Bioparticles offers custom services to help help researchers and diagnostic manufacturers develop homogeneous luminescence assays. To learn more about CD Bioparticles’ assay development services or to request a project consultation, please visit CD Bioparticles official website at: https://www.cd-bioparticles.com/services/homogeneous-luminescence-assay-development.html. About CD Bioparticles CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. The company also offers various custom services, including chemical surface-functionalization, fluorescent modification, antibody immobilization, as well as nucleic acid and oligo conjugation to meet client specifications.

Advanced Microneedle Device Customization Services to Accelerate Transdermal Drug Delivery Innovation

Custom Services and Assay Kits for Detecting Cytokines with Homogeneous Luminescence Assay